

Jörg Wissel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/592602/publications.pdf>

Version: 2024-02-01

35
papers

2,182
citations

430874

18
h-index

395702

33
g-index

41
all docs

41
docs citations

41
times ranked

1852
citing authors

#	ARTICLE	IF	CITATIONS
1	Occurrence and Clinical Predictors of Spasticity After Ischemic Stroke. <i>Stroke</i> , 2010, 41, 2016-2020.	2.0	315
2	European consensus table on the use of botulinum toxin type A in adult spasticity. <i>Journal of Rehabilitation Medicine</i> , 2009, 41, 13-25.	1.1	282
3	Toward an epidemiology of poststroke spasticity. <i>Neurology</i> , 2013, 80, S13-9.	1.1	245
4	Early development of spasticity following stroke: a prospective, observational trial. <i>Journal of Neurology</i> , 2010, 257, 1067-1072.	3.6	240
5	Management of Spasticity Associated Pain with Botulinum Toxin A. <i>Journal of Pain and Symptom Management</i> , 2000, 20, 44-49.	1.2	184
6	Pathophysiology of spasticity in stroke. <i>Neurology</i> , 2013, 80, S20-6.	1.1	139
7	The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view. <i>Annals of Physical and Rehabilitation Medicine</i> , 2020, 63, 554-556.	2.3	112
8	Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. <i>Neurology</i> , 2017, 88, 1321-1328.	1.1	99
9	COVID-19 pandemic. What should Physical and Rehabilitation Medicine specialists do? A clinician's perspective. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 515-524.	2.2	87
10	Post-stroke Spasticity: Predictors of Early Development and Considerations for Therapeutic Intervention. <i>PM and R</i> , 2015, 7, 60-67.	1.6	73
11	Identifying unmet needs in long-term stroke care using in-depth assessment and the Post-Stroke Checklist – The Managing Aftercare for Stroke (MAS-I) study. <i>European Stroke Journal</i> , 2018, 3, 237-245.	5.5	51
12	Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). <i>Journal of Medical Economics</i> , 2014, 17, 618-625.	2.1	48
13	OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 17-26.	1.2	42
14	A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2018, 54, 605-617.	2.2	38
15	Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 642-650.	1.9	30
16	Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. <i>Stroke</i> , 2018, 49, 2129-2137.	2.0	26
17	A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus. <i>Journal of Rehabilitation Medicine</i> , 2021, 53, jrm00134.	1.1	26
18	Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity – Insights from recent studies. <i>Toxicon</i> , 2018, 147, 100-106.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. <i>Frontiers in Neurology</i> , 2020, 11, 104.	2.4	19
20	Early clinical predictors of post stroke spasticity. <i>Topics in Stroke Rehabilitation</i> , 2021, 28, 508-518.	1.9	14
21	Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post-stroke spastic movement disorder: updated perspectives on best practice. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 27-42.	2.8	14
22	Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 51.	2.4	11
23	Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. <i>Annals of Physical and Rehabilitation Medicine</i> , 2021, 64, 101376.	2.3	9
24	Early brain imaging predictors of post-stroke spasticity. <i>Journal of Rehabilitation Medicine</i> , 2021, 53, jrm00169.	1.1	7
25	Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. <i>Toxins</i> , 2021, 13, 887.	3.4	7
26	Post hoc analysis of shoulder spasticity and safety following treatment with incobotulinumtoxinA. <i>Journal of Rehabilitation Medicine</i> , 2020, 52, jrm00028.	1.1	6
27	Ergonomic Recommendations in Ultrasound-Guided Botulinum Neurotoxin Chemodenervation for Spasticity: An International Expert Group Opinion. <i>Toxins</i> , 2021, 13, 249.	3.4	6
28	Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study. <i>Disability and Rehabilitation</i> , 2020, , 1-7.	1.8	5
29	Post-Stroke Spasticity. , 2021, , 149-173.		5
30	Validity and Reliability of the Spasticity-Associated Arm Pain Scale. <i>Journal of Pain Management & Medicine</i> , 2017, 03, .	0.2	5
31	What clinicians and patients want: The past, the presence, and the future of the botulinum toxins. <i>Toxicon</i> , 2020, 177, 46-51.	1.6	4
32	European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. <i>Journal of Rehabilitation Medicine</i> , 2021, .	1.1	4
33	Pathophysiology of Spasticity and Therapeutic Approach. <i>Biosystems and Biorobotics</i> , 2018, , 449-469.	0.3	1
34	Botulinum Toxin Services for Neurorehabilitation: Recommendations for Challenges and Opportunities during the COVID-19 Pandemic. <i>Toxins</i> , 2021, 13, 584.	3.4	1
35	Module 2. <i>The Journal of the International Society of Physical and Rehabilitation Medicine</i> , 2022, 5, S23-S37.	0.3	1